

DEALS AND SUITS

Certara, Inc. completes US\$135 million sale of its Regulatory and Medical Writing business to Veristat

On May 8, 2026, Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, completed the sale of its Regulatory and Medical Writing business to Veristat for total consideration of US\$135 million.

BLG acted for Certera, Inc. on the Canadian aspects with a team led by Neil Hazan that included Vinay Desai and Stephen Roumeliotis (Corporate/M&A); Stuart Aronovitch and Laura Mensch (Labour & Employment).